|Articles|July 30, 2015

Video: CFO Simon Dingemans on GSK's Q2 Results

July 30, 2015.

In this video

, GlaxoSmithKline CFO Simon Dingemans relays the company's Q2 2015 results, rhe first since the Novartis transaction closed. Despite a slide in the sales of lung drug Advair and lower profit margins following a business revamp, Dingemans says sales rose during the period and that newly acquired businesses are performing in line with expectations.

http://www.3bnexus.com/portal/video/6hdb24abf34c8cc

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Video: CFO Simon Dingemans on GSK's Q2 Results

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

The ROI of Smarter Trials: Q&A with Raj Indupuri

Trending on PharmExec

The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market

Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion

Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

Catalent Announces Expanded Partnership with Nanoscope Therapeutics

Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization